NCT06994845View on ClinicalTrials.gov

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 8, 2025

Primary Completion Date

June 28, 2030

Study Completion Date

June 30, 2030

Conditions
Primary Immunoglobulin A Nephropathy (IgAN)
Interventions
DRUG

iptacopan

Cohort 1 (12 to \< 18 years of age): Iptacopan 200 mg b.i.d.(twice daily) Cohort 2 (2 to \< 12 years old): Dosing tbd

Trial Locations (3)

19104

Childrens Hospital of Philadelphia, Philadelphia

80045

Childrens Hospital Colorado, Aurora

84113

Utah Childrens Hospital, Salt Lake City

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY